Corner Therapeutics
Watertown, Massachusetts, United States · Biotechnology, Health Care, research · 35 employees
Corner is pioneering a new class of immunotherapies. Our versatile dendritic cell hyperactivation (hDC) platform is unique in its ability to address a virtually unbounded range of cancers and infectious diseases. Our platform technology induces exceptional memory T cell responses that provide robust and durable immunity. Corner seeks to transform standard of care, ushering in a new era of robust,
Funding history
- Funding Round — $16.8M — Oct 2025
- Funding Round — $58.5M — Aug 2025
- Funding Round — $53.4M — Apr 2025
- Funding Round — $58.5M — Apr 2024
- Series series a — $54.0M — Apr 2024
Recent signals
- Oct 20, 2025: Raised $16.8M
- Aug 11, 2025: Raised $58.5M
- Apr 30, 2025: Raised $53.4M
- Apr 23, 2024: Raised $58.5M
- Apr 19, 2024: Raised $54.0M in Series series a
See plans & pricing → Track Corner Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.